Annual Report & Accounts and AGM Notification

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Annual Report & Accounts and AGM Notification

10 November 2020 - Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that it has published the 2020 Annual report and accounts and the Notice of Annual General Meeting ("AGM") on the Company's website at www.allergytherapeutics.com. Hard copies have been sent to shareholders who have requested this.

Allergy Therapeutics intends to hold its Annual General Meeting (AGM) electronically on Tuesday 8 December 2020, commencing at 2:00 p.m GMT. The AGM is an important event in the Company's corporate calendar and usually provides an opportunity for the Company's Directors to engage with shareholders. We remain committed to ensuring that shareholders can exercise their right to vote and ask questions at the upcoming AGM. However, in light of the compulsory government measures in force in response to the COVID-19 pandemic, and with the health and well-being of our colleagues, shareholders and the wider community in which we operate in mind, the AGM this year will be run as a virtual meeting in accordance with the provisions of the Corporate Insolvency and Governance Act 2020. Shareholders are therefore not able to attend the AGM in person. We will arrange for a quorum to be in place to transact the formal business of the AGM.

The Board is arranging a listen-only webinar facility to allow shareholders to attend the AGM and follow proceedings remotely. The webinar details will be published on the homepage of the Company's website (www.allergytherapeutics.com) approximately 72 hours before the date and time of the meeting. The business of the AGM will be routine business only, which is required to be dealt with in order to ensure that the Company complies with the relevant legal requirements. As such shareholders should note that the meeting itself will deal only with proposing and voting on the Resolutions set out in the Notice. There will be no Board presentation or live Q&A session with the Board. Shareholders can submit questions for the Board in advance of the AGM by email to [email protected] and the Board answer such questions at the Meeting.  

-   ENDS   -

For further information, please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott, David Daley, Ashley Tapp, Olivia Manser

[email protected]

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

[email protected]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.